Foteini Paradeisi, Aggeliki Tserga, Vasiliki Lygirou, Manousos Makridakis, Rafael Stroggilos, Grigoris Georgiou, George M. Spyrou, Ioannis V. Kostopoulos, Christine-Ivy Liacos, Aikaterini Termentzi, Meletios A. Dimopoulos, Ourania Tsitsilonis, Antonia Vlahou, Efstathios Kastritis, Jerome Zoidakis
{"title":"骨髓CD138+细胞的蛋白质组学分析鉴定与多发性骨髓瘤患者对常用治疗方案的反应相关的蛋白质","authors":"Foteini Paradeisi, Aggeliki Tserga, Vasiliki Lygirou, Manousos Makridakis, Rafael Stroggilos, Grigoris Georgiou, George M. Spyrou, Ioannis V. Kostopoulos, Christine-Ivy Liacos, Aikaterini Termentzi, Meletios A. Dimopoulos, Ourania Tsitsilonis, Antonia Vlahou, Efstathios Kastritis, Jerome Zoidakis","doi":"10.1002/pmic.70025","DOIUrl":null,"url":null,"abstract":"<p>Multiple myeloma (MM) remains incurable; gaps in our understanding of MM molecular pathogenesis and drugs’ resistance mechanisms are involved in the failure of therapies. This study aims to identify proteins significantly impacting MM patients’ response to commonly used therapeutic regimens. Bone marrow CD138+ selected plasma cells were isolated from patients who had achieved Response (Responders, R) and those who were Non-Responders (NR) to their primary MM therapy. We used LC-MS/MS to investigate the proteomic profile of MM samples, followed by bioinformatics analysis. We identified 1190 proteins, of which 230 showed a statistically significant difference between R and NR, with 27 proteins being upregulated and 203 downregulated in R compared to NR. Pathway enrichment analysis identified pathways related to the immune response and protein synthesis regulation, closely associated with MM progression and response to therapy. The results were validated through individual RNA dataset analysis, corroborating the differential expression of several proteins, including proteins associated with MM (e.g., MIF, ILF3) as well as novel findings (e.g., DCPS and SET). Collectively, proteomics data obtained from R and NR to MM therapy displayed significant changes in the immune system and protein synthesis regulation, supporting their potential role in progression and therapeutic response of MM.</p>","PeriodicalId":224,"journal":{"name":"Proteomics","volume":"25 16","pages":"48-60"},"PeriodicalIF":3.9000,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/epdf/10.1002/pmic.70025","citationCount":"0","resultStr":"{\"title\":\"Proteomic Analysis of Bone Marrow CD138+ Cells to Identify Proteins Associated With the Response of Multiple Myeloma Patients to Commonly Used Therapeutic Regimens\",\"authors\":\"Foteini Paradeisi, Aggeliki Tserga, Vasiliki Lygirou, Manousos Makridakis, Rafael Stroggilos, Grigoris Georgiou, George M. Spyrou, Ioannis V. Kostopoulos, Christine-Ivy Liacos, Aikaterini Termentzi, Meletios A. Dimopoulos, Ourania Tsitsilonis, Antonia Vlahou, Efstathios Kastritis, Jerome Zoidakis\",\"doi\":\"10.1002/pmic.70025\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Multiple myeloma (MM) remains incurable; gaps in our understanding of MM molecular pathogenesis and drugs’ resistance mechanisms are involved in the failure of therapies. This study aims to identify proteins significantly impacting MM patients’ response to commonly used therapeutic regimens. Bone marrow CD138+ selected plasma cells were isolated from patients who had achieved Response (Responders, R) and those who were Non-Responders (NR) to their primary MM therapy. We used LC-MS/MS to investigate the proteomic profile of MM samples, followed by bioinformatics analysis. We identified 1190 proteins, of which 230 showed a statistically significant difference between R and NR, with 27 proteins being upregulated and 203 downregulated in R compared to NR. Pathway enrichment analysis identified pathways related to the immune response and protein synthesis regulation, closely associated with MM progression and response to therapy. The results were validated through individual RNA dataset analysis, corroborating the differential expression of several proteins, including proteins associated with MM (e.g., MIF, ILF3) as well as novel findings (e.g., DCPS and SET). Collectively, proteomics data obtained from R and NR to MM therapy displayed significant changes in the immune system and protein synthesis regulation, supporting their potential role in progression and therapeutic response of MM.</p>\",\"PeriodicalId\":224,\"journal\":{\"name\":\"Proteomics\",\"volume\":\"25 16\",\"pages\":\"48-60\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2025-08-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/epdf/10.1002/pmic.70025\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Proteomics\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/pmic.70025\",\"RegionNum\":4,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"BIOCHEMICAL RESEARCH METHODS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Proteomics","FirstCategoryId":"99","ListUrlMain":"https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/pmic.70025","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
Proteomic Analysis of Bone Marrow CD138+ Cells to Identify Proteins Associated With the Response of Multiple Myeloma Patients to Commonly Used Therapeutic Regimens
Multiple myeloma (MM) remains incurable; gaps in our understanding of MM molecular pathogenesis and drugs’ resistance mechanisms are involved in the failure of therapies. This study aims to identify proteins significantly impacting MM patients’ response to commonly used therapeutic regimens. Bone marrow CD138+ selected plasma cells were isolated from patients who had achieved Response (Responders, R) and those who were Non-Responders (NR) to their primary MM therapy. We used LC-MS/MS to investigate the proteomic profile of MM samples, followed by bioinformatics analysis. We identified 1190 proteins, of which 230 showed a statistically significant difference between R and NR, with 27 proteins being upregulated and 203 downregulated in R compared to NR. Pathway enrichment analysis identified pathways related to the immune response and protein synthesis regulation, closely associated with MM progression and response to therapy. The results were validated through individual RNA dataset analysis, corroborating the differential expression of several proteins, including proteins associated with MM (e.g., MIF, ILF3) as well as novel findings (e.g., DCPS and SET). Collectively, proteomics data obtained from R and NR to MM therapy displayed significant changes in the immune system and protein synthesis regulation, supporting their potential role in progression and therapeutic response of MM.
期刊介绍:
PROTEOMICS is the premier international source for information on all aspects of applications and technologies, including software, in proteomics and other "omics". The journal includes but is not limited to proteomics, genomics, transcriptomics, metabolomics and lipidomics, and systems biology approaches. Papers describing novel applications of proteomics and integration of multi-omics data and approaches are especially welcome.